Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity
- PMID: 7373370
- DOI: 10.3171/jns.1980.52.4.0453
Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity
Abstract
The fibrinolytic activity in cerebrospinal fluid has been monitored by determination of levels of fibrin split products (FSP) in 23 patients with ruptured intracranial aneurysms. In 20 of these 23, FSP was found in the cerebrospinal fluid (CSF), with levels ranging from 10 to 80 micrograms/ml. Eleven of the 23 patients were treated with 2 gm tranexamic acid daily. In these patients FSP was found in only two cases during the 2nd week, while in 12 untreated patients it was found in 10 cases. These results suggest that there exists a localized fibrinolytic activity, and monitoring the FSP levels in the CSF may be a simple and accurate method for controlling the efficiency of antifibrinolytic therapy. Thus, treatment could be begun with a lower dose, which could be increased later as deemed necessary from the results of careful monitoring.
Similar articles
-
Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial.Ann Neurol. 1978 Jun;3(6):502-4. doi: 10.1002/ana.410030607. Ann Neurol. 1978. PMID: 354483 Clinical Trial.
-
Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm.Neurology. 1981 Mar;31(3):316-22. doi: 10.1212/wnl.31.3.316. Neurology. 1981. PMID: 7010208 Review.
-
Antifibrinolytic therapy in ruptured intracranial aneurysm through repeated monitoring of fibrinolytic activity of blood.Neurol Med Chir (Tokyo). 1976;16(PT1):91-6. doi: 10.2176/nmc.16pt1.91. Neurol Med Chir (Tokyo). 1976. PMID: 66644 No abstract available.
-
Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage.J Clin Pathol Suppl (R Coll Pathol). 1980;14:68-73. J Clin Pathol Suppl (R Coll Pathol). 1980. PMID: 7000850 Free PMC article. Clinical Trial. No abstract available.
-
Monitoring of fibrin and fibrinogen degradation products (FDP) in the cerebrospinal fluid of patients with subarachnoid haemorrhage due to ruptured aneurysm. Report of 55 cases.J Neurosurg Sci. 1994 Jun;38(2):77-86. J Neurosurg Sci. 1994. PMID: 7891197 Review.
Cited by
-
Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.Acta Neurochir (Wien). 1990;102(1-2):1-10. doi: 10.1007/BF01402177. Acta Neurochir (Wien). 1990. PMID: 2407050 Clinical Trial.
-
Antifibrinolytic treatment in subarachnoid haemorrhage: present state.Acta Neurochir (Wien). 1982;63(1-4):233-44. doi: 10.1007/BF01728877. Acta Neurochir (Wien). 1982. PMID: 7048863 Review.
-
Antifibrinolytic agents in subarachnoid haemorrhage.J Neurol. 1987 Jan;234(1):1-8. doi: 10.1007/BF00314000. J Neurol. 1987. PMID: 3546604 Review.
-
Determination of tranexamic acid (AMCA) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage.Acta Neurochir (Wien). 1981;58(1-2):1-13. doi: 10.1007/BF01401679. Acta Neurochir (Wien). 1981. PMID: 7282453
-
Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid.Acta Neurochir (Wien). 1990;103(3-4):116-21. doi: 10.1007/BF01407517. Acta Neurochir (Wien). 1990. PMID: 2205078 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical